Robinhood’s Earnings Soar Thanks to Cryptocurrency Tradingby John Darbie 08.08.2024Robinhood's Q2 earnings soar with a 161% surge in cryptocurrency trading. Discover the key factors behind this financial milestone.
Nevro Corp. Reports Q2 2024 Earnings: Revenue Down 4.3%by Mark Eisenberg 08.08.2024Nevro Corp. Q2 2024 revenue fell 4.3% due to competitive pressures. The company is exploring strategic options for growth.
Global Net Lease Reports Net Loss Despite Strong Leasing Activityby Mark Eisenberg 08.08.2024Global Net Lease Inc. reported a net loss in Q2 2024 despite strong leasing activity and strategic asset dispositions.
Understanding the Risks of Trading on Marginby Mark Eisenberg 08.08.2024Trading on margin can amplify gains but also significantly increase financial risks. Learn the essentials before diving in.
Treace Medical Concepts Sees 6% Revenue Boost in Q2 2024by Mark Eisenberg 07.08.2024Treace Medical Concepts reported a 6% rise in Q2 revenue to $44.5M, driven by new products and a growing surgeon ...
BTB REIT Q2 Results: Mixed Outcomes Amid Market Fluctuationsby Mark Eisenberg 07.08.2024BTB REIT reports mixed Q2 results with record occupancy but declining FFO per unit. Financial strategies and market shifts impact ...
Ascent Sees Growth and Operational Efficiency Gains in Q2 2024by Mark Eisenberg 07.08.2024Ascent (ASC) reports strong Q2 2024 results with best consolidated EBITDA since Q4 2022, amid proactive cost-cutting and strategic growth ...
Jack in the Box Reports Q3 2024 Earnings Amid Sales Declineby Mark Eisenberg 07.08.2024Jack in the Box Q3 2024 earnings show a 2.2% sales decline. Company plans include digital growth and new Chicago ...
Supernus Pharmaceuticals Reports Strong Q2 2024 Growthby Mark Eisenberg 07.08.2024Supernus Pharmaceuticals sees a 24% YoY revenue increase in Q2 2024, driven by key drugs Qelbree and GOCOVRI.
Veracyte Reports Strong Q2 Growth with 27% Revenue Increaseby Mark Eisenberg 07.08.2024Veracyte's Q2 revenue surged 27% to $114.4M, fueled by strong demand for genomic tests. Full-year guidance raised to $432M-$438M.